



Published in final edited form as:

Cell Rep. 2022 April 26; 39(4): 110760. doi:10.1016/j.celrep.2022.110760.

## Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer

Sohail Jahid, Jose A. Ortega, Linh M. Vuong, Isabella Maria Acquistapace, Stephanie J. Hachey, Jessica L. Flesher, Maria Antonietta La Serra, Nicoletta Brindani, Giuseppina La Sala, Jacopo Manigrasso, Jose M. Arencibia, Sine Mandrup Bertozzi, Maria Summa, Rosalia Bertorelli, Andrea Armirotti, Rongsheng Jin, Zheng Liu, Chi-Fen Chen, Robert Edwards, Christopher C.W. Hughes, Marco De Vivo\*, Anand K. Ganesan\*

In the original version of this article that was published on April 5, 2022, the main text reports that a structure-based screen was carried out in SKMeL28 cells, but the flowchart in Figure 2A erroneously indicated that the screen was carried out in SKMeL3 cells. The figure now appears correctly online, and the authors sincerely regret the errors and any confusion they may have caused.




Figure 2A. Structure-based screening identifies RHOJ/CDC42 allosteric inhibitors with broad-spectrum anti-cancer activity (corrected)




Figure 2A. Structure-based screening identifies RHOJ/CDC42 allosteric inhibitors with broad-spectrum anti-cancer activity (original)

\*Correspondence: marco.devivo@iit.it (M.D.V.), aganesan@uci.edu (A.K.G.).